Producing cell therapies isn’t easy—and that’s a fact Bristol Myers Squibb knows only too well. FDA hang-ups at a viral vector plant delayed CAR-T therapy Breyanzi, sinking a Celgene deal-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results